Brasilia – The National Health Surveillance Agency (Anvisa) on Friday (17) approved the indication of the drug baricitinib, which is intended for arthritis and dermatitis, to treat patients in hospital against Covid-19, who need oxygen through a mask or nasal catheter or who need an infusion of oxygen Higher or non-invasive ventilation.
According to the health regulatory agency, the indication is curative, as the drug is registered in Brazil for the treatment of moderate to severe active rheumatoid arthritis and moderate to severe atopic dermatitis.
According to Anvisa, the drug baricitinib is indicated for the treatment of Covid-19 curative (Photo: Tiago Queiroz/Estadão)
Baricitinib is a selective and reversible inhibitor of Janus kinases (JAKs), particularly JAK 1 and 2, which is responsible for cell communication involved in hematopoiesis (the process of formation and development of blood cells), inflammation and immune function (the body’s defense function).
Anvisa also highlighted that for the inclusion of the new indication, the manufacturer Eli Lilly do Brasil provided data supporting the efficacy and safety of the drug for this purpose.
Andrea Hargraves is a contributor to Brytfmonline.com, covering a broad range of topics including news, politics, business, technology, sports, entertainment, and lifestyle. She is committed to delivering clear, accurate, and reader-focused reporting that helps audiences stay informed about current events and emerging developments. Andrea’s work emphasizes useful information, balanced coverage, and stories that matter to everyday readers, making complex topics accessible and relevant to a wide audience.